Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Sun, Jul 12, 2026

1 updates

7:30 PM

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

astellas.com

Mon, Jul 6, 2026

1 updates

10:30 PM

China’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancer

astellas.com

Tue, Jun 23, 2026

1 updates

7:30 PM

European Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancer

astellas.com

Fri, May 29, 2026

1 updates

3:00 AM

Notice Regarding the Resignation of an Outside Director and Partial Withdrawal of Matters to be Resolved at the 21st Term Annual Shareholders Meeting

astellas.com

Thu, May 28, 2026

1 updates

11:00 PM

Astellas’ View on ISS Voting Recommendations

astellas.com

Tue, May 26, 2026

2 updates

2:45 AM

We have announced our Corporate Strategic Plan 2026 (CSP2026)

astellas.com

2:30 AM

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

astellas.com

Thu, May 21, 2026

1 updates

7:30 PM

PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy

astellas.com

Mon, May 18, 2026

1 updates

7:30 PM

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026, 2:45 PM CDTastellas.com

Thu, May 14, 2026

4 updates

10:30 PM

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme

astellas.com

10:30 PM

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives

astellas.com

7:30 PM

China’s National Medical Products Administration Accepts New Drug Application for IZERVAY™ (avacincaptad pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

astellas.com

2:00 AM

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

astellas.com

Tue, May 12, 2026

1 updates

10:14 AM

IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients

Presentation / Abstract • Phase 3ARVO presentation Tue, May 12, 2026astellas.com

Mon, Apr 27, 2026

4 updates

2:31 AM

Financial Results of Astellas for FY2025

astellas.com

2:30 AM

Notice of Nominees for Directors

astellas.com

2:30 AM

Astellas Announces Personnel Change

astellas.com

2:30 AM

Notice Regarding Impairment Loss and Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)

astellas.com

Thu, Apr 23, 2026

1 updates

10:30 PM

Astellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®

astellas.com